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T cell alloreactivity is mediated by a self-human leukocyte antigen (HLA)-restricted T cell 
receptor (TCR) repertoire able to recognize both structurally similar and dissimilar allo-
geneic HLA molecules (i.e., differing by a single or several amino acids in their peptide- 
binding groove). We hypothesized that thymic selection on self-HLA molecules could 
have an indirect impact on the size and diversity of the alloreactive response. To test this 
possibility, we used TCR Vβ immunophenotyping and immunosequencing technology 
in a model of alloreactivity between self-HLA selected T cells and allogeneic HLA-DPB1 
(DPB1) differing from self-DPB1*04:02 by a single (DPB1*02:01) or several (DPB1*09:01) 
amino acids in the peptide-binding groove. CD4+ T  cells from three different self-
DPB1*04:01,*04:02 individuals were stimulated with HeLa cells stably transduced with 
the relevant peptide processing machinery, co-stimulatory molecules, and HLA-DP. Flow 
cytometric quantification of the DPB1-specific T cell response measured as upregulation 
of the activation marker CD137 revealed significantly lower levels of alloreactivity against 
DPB1*02:01 compared with DPB1*09:01 (mean CD4+CD137+ frequency 35.2 ± 9.9 
vs. 61.5 ± 7.7%, respectively, p < 0.0001). These quantitative differences were, how-
ever, not reflected by differences in the breadth of the alloreactive response at the Vβ 
level, with both alloantigens eliciting specific responses from all TCR-Vβ specificities 
tested by flow cytometry, albeit with higher levels of reactivity from most Vβ specificities 
against DPB1*09:01. In line with these observations, TCRB-CDR3 immunosequencing 
showed no significant differences in mean clonality of sorted CD137+CD4+ cells allo-
reactive against DPB1*02:01 or DPB1*09:01 [0.39 (0.36–0.45) and 0.39 (0.30–0.46), 
respectively], or in the cumulative frequencies of the 10 most frequent responding clones 
(55–67 and 58–62%, respectively). Most of the clones alloreactive against DPB1*02:01 
(68.3%) or DPB1*09:01 (75.3%) were characterized by low-abundance (i.e., they were 
not appreciable among the pre-culture T cells). Interestingly, however, their cumulative 
frequency was lower against DPB1*02:01 compared with DPB1*09:01 (mean cumula-
tive frequency 35.3 vs. 50.6%, respectively). Our data show that, despite lower levels 
TaBle 1 | HLA, CMV, and demographic data for the healthy subjects used in 
this study.
subject DPB1 typing cMV serostatus age (years) gender
R1 *04:01,*04:02 Negative 67 Male
R2 *04:01,*04:02 Negative 56 Male
R3 *04:01,*04:02 Negative 21 Female
CMV, cytomegalovirus; HLA, human leukocyte antigen; R, responder.
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of alloreactivity, a similar clonal diversity can be elicited by structurally similar compared 
with structurally dissimilar HLA-DPB1 alloantigens and demonstrate the power of TCRB 
immunosequencing in unraveling subtle qualitative changes not appreciable by conven-
tional methods.
Keywords: T-cell alloreactivity, T-cell receptor repertoire, next-generation sequencing, human leukocyte antigen-
DPB1, permissive mismatches
inTrODUcTiOn
T cell alloreactivity against the human leukocyte antigen (HLA) 
system is a major barrier to successful transplantation of organs 
and stem cells. Alloreactivity is mediated by a T cell repertoire 
shaped by thymic selection to be self-HLA restricted, but at the 
same time capable of recognizing non-self-HLA. The fact that a 
large proportion of T cells is capable of recognizing previously 
unseen alloantigens (1, 2) remains an enigma of T cell biology. 
T  cell alloreactivity involves a complex interplay between the 
polymorphic foreign HLA molecule, the peptides being pre-
sented by it, and the self T cell receptor (TCR) (3). Although the 
relative contribution of each of these components to alloreactivity 
is not completely understood, it is conceivable that amino acid 
changes in the peptide-binding region of a given HLA molecule 
may ensue changes in the biochemical and/or structural proper-
ties of the binding pockets, thereby impacting the amino acid 
sequence and/or conformation of peptides able to be presented 
by it. Alternatively, these amino acid changes could directly affect 
the interaction between the HLA molecule and the TCR (4). 
Whether the number of amino acid differences in the peptide-
binding region of the HLA molecule results in higher or lower 
levels of alloreactivity and whether this arises from a broader or 
narrower alloreactive T cell response is a matter of debate.
Of note, it has been shown that even a single amino acid dif-
ference in the peptide-binding region of HLA class I molecules 
HLA-B*44:02 and B*44:03 can elicit a T cell response sufficient 
to cause allograft rejection (5) or graft-vs.-host disease (GvHD) 
(6) after hematopoietic stem cell transplantation (HSCT). In 
addition, in  vitro measurements of the patient–donor immune 
response before HSCT, mainly based on direct recognition of 
mismatched HLA class I antigens, have suggested that the number 
of amino acid differences is inversely correlated with the amount 
of direct T cell allorecognition (7), although this concept was not 
supported by clinical associations with HSCT outcome (8). Our 
understanding, control, and capacity to harness alloreactivity in 
the transplantation setting are still incomplete.
HLA-DPB1 (DPB1) represents an attractive model for the 
study of alloreactive responses to HLA molecules. Previous work 
by us (9) and others (10, 11) has shown differential alloreactivity 
to allogeneic DPB1 according to a functional classification of its 
different allelic variants (12). Amino acid changes resulting in 
structural and functional dissimilarities between DPB1 alleles 
were shown to have a strong median impact on alloreactive 
responses to these molecules (13), allowing for the classification 
of DPB1 mismatches as permissive (structural similarity and low 
alloreactivity) or non-permissive (structural dissimilarity and 
higher alloreactivity) in the clinical setting (14, 15). Importantly, 
the classification of a mismatch as permissive or non-permissive 
depends on the self-HLA background of the responder, follow-
ing the concepts of thymic T cell education (16). However, direct 
evidence for the hypothesis that thymic selection on self-alleles 
has an indirect impact on the size and diversity of the alloreac-
tive response has yet to be obtained. Here, we have sought to fill 
this gap by characterizing the alloreactive TCR diversity from 
self-DPB1*04:01,*04:02 individuals against alloantigens carrying 
a single (DPB1*02:01) or multiple (DPB1*09:01) amino acid 
differences in the peptide-binding groove using a unique system 
of single-DPB1 allele-expressing cells, and TCR Vβ immunophe-
notype and deep immunosequencing of the TCRB gene.
MaTerials anD MeThODs
subjects and cells
Buffy coats from three healthy blood donors were obtained in 
order to isolate peripheral blood mononuclear cells (PBMC) 
by Ficoll centrifugation. All blood donors had been typed as 
self-DPB1*04:01,*04:02 by standard molecular methods and 
were CMV seronegative. Demographic details of each subject 
are presented in Table  1. PBMC were then used to isolate 
untouched CD4+ T  cells via magnetic beads according to the 
manufacturer’s instructions (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany). Purified CD4+ T  cells (average 97.7%, 
range: 96.7–98.3% of live cells, with a CD8+ mean content of 
0.02%, range: 0.01–0.04%) were used as responders in coculture 
with stimulating cells as described subsequently. All participants 
gave informed consent, and this study was approved by the local 
ethics committee of University Hospital Essen.
expansion of DPB1-specific cD4+ cells
In order to expand DPB1-specific alloreactive T cells, purified 
CD4+ cells from each donor were cocultured with HeLa cells 
expressing single specific HLA-DP molecules as described previ-
ously (17, 18). In brief, HeLa cells, which normally do not express 
HLA class II molecules, were retrovirally transduced with specific 
HLA-DP molecules (DPB1 and the naturally associated DPA1 
3Arrieta-Bolaños et al. Alloreactive TCR Diversity against HLA-DP
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 280
FigUre 1 | Continued
FigUre 1 | Alloresponses from self-DPB1*04:01,*04:02 individuals against HLA-DPB1*02:01 and DPB1*09:01 result in stronger responses against the latter. 
Isolated untouched CD4+ T cells from the three self-DPB1*04:01/*04:02 responders (R) were cocultured with HeLa cells expressing DPB1*02:01 or DPB1*09:01. 
After 2 weeks, expanded alloreactive T cells were restimulated for 24 h against HeLa cells expressing the original DPB1 alloantigen or an autologous allele, and the 
degree of T cell response was quantified as the proportion of CD4+CD137+ cells. (a) Gating strategy: cells are gated on the live cells and CD3+CD4+ cells. (B) 
Representative responses from each of the subjects. Left panels, background response of alloreactive cells against the autologous allele DPB1*04:01; middle 
panels, response against allogeneic DPB1*02:01; and right panels, response against allogeneic DPB1*09:01. (c) The specific response against each allele was 
quantified in parallel repeats (n = 8) for each subject after deduction of the background levels of CD137 positivity against HeLa expressing the autologous allele 
(average 4.11%). Mean response (and SD) against DPB1*02:01 and DPB1*09:01 was 35.2% (9.95) and 61.54% (7.69), respectively (p < 0.0001).
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genes) and the necessary machinery for HLA class II antigen 
presentation (HLA-DM and invariant chain) and co-stimulation 
(CD80) and used as antigen-presenting cells. Expression of the 
DP heterodimer was confirmed by flow cytometry (anti-DP 
clone B7/21; Leinco Technologies, Inc., St. Louis, MO, USA) 
with comparable levels among different transduced cells (data 
not shown). Purified CD4+ T cells (typically 1.2 million) were 
cultured in RPMI (c.c.pro GmbH, Oberdorla) supplemented 
with l-glutamine (2  mM), penicillin–streptomycin (100  ng/
mL), and 10% human AB serum at a ratio of 3:1 with irradiated 
(100 Gy) HeLa cells in the presence of 50 U/mL IL-2 in 24-well 
plates. Parallel cocultures were set up for each subject using HeLa 
expressing DPB1*02:01 (one peptide-binding groove amino 
acid difference with DPB1*04:02) or DPB1*09:01 (10 peptide-
binding groove amino acid differences with DPB1*04:02). After 
15 days, expanded CD4+ T cells were rechallenged for 24 h with 
HeLa expressing the allogeneic stimulator DPB1 at the same 
ratio in order to assess the alloreactive response in terms of 
CD137+ (i.e., activated) T  cells by flow cytometry (19). HeLa 
cells transduced to express one of the donors’ self-HLA DPB1 
molecules (i.e., *04:01) were used to determine background 
activation levels (average 4.1%). After rechallenge, T cells were 
stained with fluorescently labeled antibodies against CD3 (clone 
UCHT1, Beckman Coulter, Marseille, France), CD4 (clone SK3, 
BD Biosciences, Heidelberg, Germany), CD8 (clone B9.11, 
Beckman Coulter, Marseille, France), and CD137 (clone 4B4-1, 
BD Biosciences, Heidelberg, Germany), and the proportion of 
CD137+CD4+ cells was measured on a Gallios flow cytometer 
(Beckman Coulter GmbH, Krefeld, Germany). CD137+CD4+ 
cells were then assessed for their TCR diversity as explained 
subsequently.
Tcr Vβ immunophenotype
T cell receptor diversity of anti-DPB1 T cell cultures was assessed 
in total and CD137+CD4+ cells at the Vβ level by flow cytometry 
using the IOTest® Beta Mark TCR Vβ Repertoire kit (Beckman 
Coulter, Marseille, France). For this, one million cultured CD4+ 
cells were restimulated with the specific HeLa transduced cells 
for 24 h. Then, the T cells were harvested and stained with subset 
markers as indicated earlier and the kit’s eight Vβ antibody 
cocktails according to manufacturer’s instructions. The frequency 
of each of the targeted Vβ specificities was recorded in the reac-
tive (CD4+CD137+) fraction. In addition, the proportion of 
CD137+ cells (responsiveness) among all CD4+ cells expressing 
each of the Vβ specificities was quantified. Pre-culture-isolated 
CD4+ cells from each subject were also analyzed in parallel as 
baseline control.
Tcr immunosequencing
Next-generation sequencing-based high-throughput TCR 
analysis (TCR immunosequencing) was carried out in DPB1 
alloreactive T cells. For this, two million cultured CD4+ cells 
were restimulated with the specific HeLa transduced cells for 
24 h, after which the T cells were harvested and sorted for CD137 
positivity (average purity 93.2%) using magnetic bead technol-
ogy according to manufacturer’s instructions (Miltenyi Biotec 
GmbH, Bergisch Gladbach). Enrichment for DPB1-specific 
alloreactive T cells was confirmed by interferon-γ Elispot assays 
(data not shown). Genomic DNA from sorted CD137+CD4+ 
cells and pre-culture-isolated CD4+ samples from each subject 
as baseline controls was subsequently extracted using a DNeasy 
Blood & Tissue Kit (QIAGEN GmbH, Hilden, Germany). DNA 
from each cultured and pre-culture sample was sequenced 
to determine TCRB complementarity-determining region 3 
(CDR3) rearrangements using the immunoSEQ® Assay from 
Adaptive Biotechnologies (Seattle, WA, USA) as described 
previously (20, 21). Briefly, a multiplex PCR system based 
on forward primers targeting 54 TRBV segments and reverse 
primers targeting 13 TRBJ segments was used to amplify the 
CDR3 region of the TCRB locus. The PCR products were 
sequenced on an Illumina HiSeq System, and reads of 87 base 
pairs covering the CDR3 region were obtained. Sequence data 
were preprocessed to remove PCR and sequencing errors in 
the primary sequence. CDR3 regions were defined based on 
alignments to sequences in the international ImMunoGeneTics 
information system® (22). All cultured samples were analyzed 
at survey resolution (targeting 60,000 T  cell genomes), while 
pre-culture samples were analyzed at deep resolution (target-
ing 200,000 T cell genomes). Average input DNA was 218.4 ng 
(range 137.9–400) for CD137+CD4+ cells and 1,200 ng for pre-
culture CD4+ cells, respectively. The number of templates (total 
T cells) and the number of rearrangements (unique T cells) in 
each sample were estimated based on synthetic template pools 
as previously described (21).
Diversity Metrics and statistical analyses
Immunosequencing data generated for each sample were ana-
lyzed for their TCR diversity in terms of clonality and richness. 
Clonality was calculated as 1-Pielou’s evenness (23), which is a 
measure of how uniformly distributed the repertoire is, and it 
is computed as normalized Shannon’s Entropy. Clonality values 
approaching 0 indicate that every rearrangement is present at 
nearly identical frequency (i.e., less variation in abundance), 
whereas values approaching 1 indicate a very skewed dis-
tribution of frequencies (i.e., more variation in abundance). 
5Arrieta-Bolaños et al. Alloreactive TCR Diversity against HLA-DP
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Richness, a measure of the number of different species in a 
repertoire was assessed using the Daley–Smith estimate (24), 
a non-parametric empirical Bayes estimator of repertoire rich-
ness based on extrapolation of the rarefaction curve to 10 times 
the actual sample size. TCR clone sharing between samples 
was assessed by overlap and differential abundance analyses 
(25), and repertoire similarity was assessed by Morisita’s index, 
a population overlap metric relating the dispersion of clones 
in the samples (26). The abundance of individual clones was 
defined by assessing their presence and frequency in pre-culture 
and cultured samples, and low abundance clones were defined as 
those seen in cultured samples but undetected in the pre-culture 
repertoire. CDR3 immunosequencing data were analyzed using 
custom bioinformatics tools [R version 3.3.2 (27) and RStudio 
version 1.0.136 (28)] and the immunoSEQ Analyzer® (Adaptive 
Biotechnologies, Seattle, WA, USA). Alloreactivity levels 
against DPB1*02:01 and DPB1*09:01 and pre-culture sample 
groups were compared using t-tests, and p-values < 0.01 were 
considered statistically significant. Statistical analyses were 
performed using Prism (version 6.05, GraphPad Software Inc., 
La Jolla, CA, USA).
resUlTs
alloreactive response against similar  
or Dissimilar DPB1 alleles
After coculture with DPB1-transduced HeLa cells, alloreactive 
T cells were obtained for all three responders studied against 
the stimulator alloantigen with either a single (DPB1*02:01, 
DPA1*01:03) or 10 (DPB1*09:01, DPA1*02:01) amino acid 
differences compared to self-DPB1*04:02. Levels of allore-
activity in our cultured samples were measured based on 
CD137 upregulation upon restimulation with the relevant 
alloantigen, and deduction of background levels of the marker 
against one of the self-alleles (i.e., DPB1*04:01, DPA1*01:03). 
Figure  1 shows the gating strategy, representative CD137 
upregulation plots for each responder, and overall results. The 
FigUre 2 | Continued
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FigUre 2 | Continued
TaBle 2 | Immunosequencing data for pre-culture and cultured samples.
sample responder (r) number of productive templates 
(total T cells)
number of rearrangements 
(unique T cells)
Productive 
clonality
Maximum clonal 
frequency (%)
Pre-culture CD4+ R1 180,066 98,044 0.0599 0.38
R2 167,264 116,092 0.0406 0.53
R3 168,885 146,063 0.0122 0.04
DPB1*02:01-specific 
CD137+CD4+ cells
R1 7,543 720 0.3909 25.76
R2 7,874 619 0.4512 26.35
R3 2,530 495 0.3572 27.94
DPB1*09:01-specific 
CD137+CD4+ cells
R1 26,837 1,175 0.4596 22.51
R2 1,447 251 0.2954 14.93
R3 9,927 959 0.3905 21.80
FigUre 2 | Alloresponses against both HLA-DPB1*02:01 and DPB1*09:01 originate from a varied repertoire at the Vβ level, but with stronger responsiveness 
against the latter. TCR-Vβ analysis of 24 Vβ specificities was performed by flow cytometry in CD4+ T cells from three self-DPB1*04:01,*04:02 responders (R) after 
2 weeks of culture with HeLa cells expressing DPB1*02:01 or DPB1*09:01, followed by overnight reincubation with HeLa cells expressing the original alloantigen. 
(a) Percentage of cells pre-culture and in the CD137+ cultured fractions after restimulation expressing each of the targeted Vβ families against each alloantigen. 
(B) Enrichment in the CD137+ cultured fraction vs. pre-culture levels (y axis) of each of the Vβ specificities was quantified and plotted against CD137 positivity for all 
cells expressing that Vβ family after restimulation (x axis). The size of each circle represents the share (% cells positive) of each Vβ specificity in the CD137+ T cell 
receptor repertoire. Vβ family dynamics against DPB1*02:01 (blue circles) and DPB1*09:01 (red circles) are shown for each responder. (c) Heat map showing 
CD137 positivity levels among all cells expressing each Vβ specificity for each of the responders against the two DPB1 alleles. Shown in red are strongly responding 
Vβ specificities (>60% CD137+ cells after restimulation among all CD4+ cells expressing that specificity). (D) Plot showing the response (CD137 levels) of each of 
the targeted Vβ specificities against DPB1*02:01 (x axis) and DPB1*09:01 (y axis) for each of the three responders. Each dot represents one targeted Vβ specificity 
for each of the responders. The majority of the Vβ specificities respond with higher CD137 levels against DPB1*09:01 than to DPB1*02:01.
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response against DPB1*02:01 was significantly lower than that 
against DPB1*09:01, with mean percentages of alloreactive 
CD137+CD4+ of 35.2% (range 23.0–49.6%) and 61.54% (range 
44.2–70.2%), respectively.
Diversity of T cell responses against 
DPB1 alleles at the Tcr-Vβ level
We first analyzed the TCR diversity among these cells at the 
level of Vβ families by using flow cytometric quantification 
(Figure  2). We observed that all Vβ specificities tested could 
be found among the DPB1*02:01 and DPB1*09:01-reactive 
CD4+ cells (Figure 2A) and that the frequency of the majority 
(12–16/24 against DPB1*02:01; 12–20/24 against DPB1*09:01) of 
targeted Vβ specificities expanded during culture, with average 
fold expansions of 3.86 against DPB1*02:01 and 3.50 against 
DPB1*09:01. There was a correlation between CD137 positivity 
in each family and fold expansion from pre-culture levels, with 
responses against DPB1*09:01 showing a shift to higher levels of 
CD137 positivity (Figure 2B). This difference was also reflected 
in the number of highly reacting Vβ specificities (i.e., Vβ for 
which >60% of all cells expressed CD137 after restimulation) 
against each allele: 1–11/24 against DPB1*02:01 vs. 18–22/24 
against DPB1*09:01 (Figure 2C). In addition, in 63/72 cases the 
same Vβ family responded with higher CD137 levels against 
DPB1*09:01 than to DPB1*02:01 (overall average 26.1% higher) 
(Figure 2D). The cumulative frequency of the top 10 Vβ specifici-
ties was similar for both alleles (63.8% against DPB1*02:01 vs. 
61.7% against DPB1*09:01). Overall, these data at the Vβ level 
suggest that responses against a single or multiple amino acid 
differences in HLA-DP arise from comparable levels of diversity, 
albeit with overall lower levels of alloreactivity against the more 
similar allele.
clonality and richness of Tcr clones 
responding against a single or Multiple 
amino acid Differences between DPB1 
alleles
We then analyzed the diversity of alloreactive DPB1-specific 
CD4+ T cells at the CDR3 level by TCRB immunosequencing. 
Table 2 shows the summary data for the immunosequencing 
results. As expected, clonality for the cultured CD137+CD4+ 
cells (mean 0.39) was higher than in pre-culture samples 
(average 0.04). However, the diversity among T  cell clones 
(as defined by their CDR3 sequence at the amino acid level) 
responding against DPB1*02:01 was comparable to those 
responding against DPB1*09:01, and mean productive clonal-
ity of TCR clones responding against DPB1*02:01 (0.40, range 
0.36–0.45) was similar to that of the clones responding against 
DPB1*09:01 (0.38, range 0.30–0.46) (Figure  3A). The clone 
richness was also markedly reduced when compared to the 
pre-culture samples, but did not differ substantially between 
clones responding against either allele (Figure  3B). The 
share for the top 10 reactive clones in the cultured samples 
ranged from 54.7 to 66.8%, with no substantial difference 
8Arrieta-Bolaños et al. Alloreactive TCR Diversity against HLA-DP
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between cultures responding against DPB1*02:01 (59.4%, 
range 58–62%) or DPB1*09:01 (mean 60.0%, range 55–67%) 
(Figure 3C). In accordance with these results, the frequency 
distribution of T-cell clones did not show any major difference 
between alloresponses against these two alleles (Figure 3D), 
with similar number of high-frequency clones (≥1%): 20, 19, 
13 against DPB1*02:01; 11, 17, 13 against DPB1*09:01 for 
R1, R2, and R3, respectively. Finally, analysis of CDR3 length 
among alloreactive clones revealed no major skewing in the 
responses against either allele in comparison to pre-culture 
samples (Figure 4). Overall, these data correlate with the Vβ 
analyses and suggest that the responding TCR clones elicited 
in vitro against a single or multiple amino acid differences in 
DPB1 do not differ substantially in terms of their size and 
diversity.
Overlap of Tcr clones responding 
against DPB1 alleles
We then asked whether there was overlap between individual 
clone sets responding against either allele and between clones 
responding against the same allele across individuals. Overall 
repertoire similarity among cultured samples was low (mean 
Morisita’s index 0.054). There was little overlap between clone 
sets responding against DPB1*02:01 and DPB1*09:01 within the 
same individual [median Morisita’s index: 0.12 (0.005–0.68)] 
(Figure 5A), and almost no overlap against the same allele across 
individuals (Figure 5B). At the amino acid level, each individual’s 
clones sets reactive against DPB1*02:01 and DPB1*09:01 shared 
only 38/1,204, 8/571, and 7/1,099 sequences (55/1,840, 13/857, and 
7/1,447 nucleotide sequences) (Figure 5A). Analysis of the 10 most 
frequent sequences revealed almost no sharing between cultures 
FigUre 3 | Continued
FigUre 3 | Diversity of CD4+ T cell responses against DPB1*02:01 and DPB1*09:01 at the CDR3 level. Immunosequencing of TCRB of sorted CD4+CD137+ cells 
was performed, and the T cell receptor (TCR) repertoire diversity measures were quantified in CD4+ T cells from three self-DPB1*04:01,*04:02 responders (R) after 
2 weeks of culture with HeLa cells expressing DPB1*02:01 or DPB1*09:01, followed by overnight reincubation with HeLa cells expressing the original alloantigen. Median 
and interquartile ranges for (a) productive clonality and (B) richness of TCR clones from each responder are plotted, including pre-culture CD4+ cells. (c) Cumulative 
frequency of the top 10 clones (blue) for each set of alloreactive clones and the pre-culture TCR repertoire is shown. Top 10 clones at the DNA (or amino acid in 
brackets) level accounted for 54.73% (56.04%), 66.83% (68.71%), and 56.56% (58.85%) against DPB1*02:01, and 62.5% (63.21%), 59.5% (63.99%), and 58.14% 
(60.80%) against DPB1*09:01 for R1, R2, and R3, respectively. Pre-culture top 10 clones at the DNA (or amino acid in brackets) level accounted for 2.14% (2.20%), 
2.39% (2.45%), and 0.29% (0.31%) for R1, R2, and R3, respectively. (D) Pie plots showing the frequency distribution for clones at the amino acid level responding 
against DPB1*02:01 (left plots), and DPB1*09:01 (right plots) for each responder. Listed are the top 10 clones for each sample. The total number of clones at the amino 
acid level was 481, 409, and 406 against DPB1*02:01, and 761, 170, and 700 against DPB1*09:01 for R1, R2, and R3, respectively.
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(Table  3; Figure  3D). Apart from a single nucleotide sequence 
shared between two individuals responding against DPB1*02:01 
and two clones against DPB1*09:01 with the same amino acid 
sequence but different nucleotide sequences, no clone was shared 
by subjects responding against the same allele (Figure 5B). Overall, 
these data suggest that, despite showing similar repertoire size 
metrics, responses against these DPB1 alleles are highly divergent, 
while responses against the same allele are highly individualized.
clonal enrichment and abundance of  
Tcr clones reacting against a single  
or Multiple amino acid Differences 
between DPB1 alleles
In order to assess clone expansion against a single or multiple 
amino acid differences in DPB1, we examined their kinet-
ics in terms of enrichment (25) and pre-culture abundance. 
FigUre 4 | Complementarity-determining region 3 (CDR3) length analysis of alloresponses against DPB1*02:01 and DPB1*09:01. The length of CDR3 regions 
(number of amino acids) as determined by immunosequencing for each responder’s (R) samples was quantified. Shown are histograms for the total pre-culture 
CD4+ cells (left panels) and cultured CD4+CD137+ cells alloreactive against DPB1*02:01 (middle panels) and DPB1*09:01 (right panels).
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Significantly enriched clones in the cultured samples with 
respect to the pre-culture repertoires accounted for a large part 
of the clones responding against DPB1*02:01 (mean cumula-
tive frequency 82.4%, range 71.82–89.26%). This was similar 
against DPB1*09:01 (mean 84.2%, range 74.5–93.3%). A total 
of 69, 52, and 33 clones against DPB1*02:01 and 172, 26, and 
105 clones against DPB1*09:01 showed statistically significant 
enrichment in cultured samples (p  <  0.01). For significantly 
enriched clones detected in the pre-culture samples, average fold 
expansions against DPB1*02:01 were 866× (range 15–6,016×), 
2,245× (6–14,693×), and 5,350× (49–47,194×), for R1, R2, 
and R3, respectively, while among clones responding against 
DPB1*09:01 they were 873× (2–32,260×), 2,012× (11–12,022×), 
and 1,396× (6–10,786×) for R1, R2, and R3, respectively. As 
shown in Figure 6, among clones detected in both the cultured 
and the pre-culture samples, apart from a few cases where higher 
frequency clones expanded strongly, those with lower pre-culture 
frequencies constitute a large part of the cultured clones, with 
no major difference between DPB1 alleles.
Due to the fact that low-abundance (i.e., rare) alloreactive T cell 
clones seem to constitute a major component of alloresponses (29), 
we evaluated their presence and cumulative frequencies among 
clones responding against DPB1*02:01 and compared them to 
responses against DPB1*09:01. We defined low-abundance pre- 
culture clones as those present in the cultured samples but not detect-
able in the respective pre-culture samples (Figure 7A). We found 
that low-abundance clones represented the majority of the clones 
identified against DPB1*02:01 (average 68.3%) and DPB1*09:01 
(average 75.3%). However, the mean cumulative frequency of 
low-abundance clones expanded against DPB1*02:01 was lower 
in comparison to those expanded against DPB1*09:01 (average 
36.3%, range 33.6–39.0% and average 50.6%, range 32.0–71.3%, 
respectively) (Figure  7B). Overall, these data show that DPB1-
specific alloreactive clones arise preferentially from low-frequency 
FigUre 5 | Responses against DPB1*02:01 and DPB1*09:01 alleles are highly divergent and individualized. The sharing of TCRB-CDR3 amino acid sequences 
among CD4+CD137+ cells responding against DPB1 alleles was compared. (a) Pairwise scatter plots showing the frequency and sharing of clones against each 
allele in each of the three responders (R). Within each responding individual, there was a low sharing of clones (purple dots) between their responses against 
DPB1*09:01 (y axis) and DPB1*02:01 (x axis). Morisita’s indexes for each pairwise T cell receptor clone set comparison are shown. (B) Venn diagrams show the 
sharing of clones across individuals against DPB1*02:01 (left panel) and DPB1*09:01 (right panel). The number of unique sequences in each clone set is depicted. 
Only one DPB1-alloreactive clone was shared across individuals for each allele.
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clones, with undetected low-abundance pre-culture T cell clones 
representing a substantial part of the alloreactive repertoires against 
HLA-DP molecules, in particular against dissimilar DPB1.
DiscUssiOn
In this study, we have characterized the self-selected (i.e., 
self-DPB1*04:01,*04:02) alloreactive CD4+ T  cell clone sets 
generated against structurally similar (DPB1*02:01) or dissimilar 
(DPB1*09:01) HLA-DP molecules in healthy individuals using Vβ 
immunophenotyping and, for the first time, cutting-edge high-
resolution immunosequencing of the TCR. Our analyses show that 
despite quantitative differences in the strength of the in vitro allore-
sponse, with higher levels of reactivity against the more dissimilar 
allele, a single amino acid difference in the peptide-binding groove 
encoded by allogeneic DPB1*02:01 compared to self-DPB1*04:02 
is able to generate an array of alloreactive TCR clones of similar 
broadness and diversity to those elicited by 10 amino acid changes 
in the peptide-binding groove encoded by allogeneic DPB1*09:01, 
with no major differences in clonality and other diversity measures 
when comparing both alloantigens. In addition, we show a very low 
overlap between the responses against both alleles at the individual 
subject level, and essentially no overlap among TCRs responding 
against the same allele across individuals. Finally, by making use 
of the unique power of immunosequencing we show that clones 
with low pre-culture frequencies appear with high frequency 
among the expanded alloreactive clones and confirm previous 
observations regarding the relevant role of low-abundance clones 
in alloreactivity (30). We suggest that this compartment might play 
a more important role in alloreactivity to more dissimilar DPB1 
alleles based on their greater share of the alloreactive clone array 
elicited by DPB1*09:01 compared with DPB1*02:01.
By using specific DPB1 mismatches (i.e., DPB1*04:01,*04:02 
vs. DPB1*02:01 or DPB1*09:01) involving a single or multiple 
amino acid changes in the HLA-DP peptide-binding groove 
with respect to one of the self-selecting alleles (i.e., DPB1*04:02), 
TaBle 3 | Top 10 CDR3 amino acid sequences for CD137+CD4+ cells.
DPB1*02:01-
specific 
cD137+cD4+ 
cells
amino acid  
sequence
Frequency 
in cultured 
sample (%)
Frequency in 
pre-culture 
sample (%)
R1 CAWSVNSNEKLFF 25.9446 0.0405
CSARGRQGAEYF 5.2897 ND
CASTLSHYGYTF 4.3219 ND
CASARGTEAFF 3.9639 ND
CASRRRVGHEQYF 3.9374 0.0128
CASSIGRRGHGNEQFF 3.3674 0.0006
CASSPIGGYGIGNEQFF 2.5321 0.0006
CASSDPAPWVSDEQFF 2.3996 0.0017
CASSYVFSFIINNEQFF 2.1477 0.0033
CASTRDSNEQFF 2.1344 0.0006
R2 CASSLGEAGGYEQYF 26.8732 0.0018
CASSLAHLRQTAYEQYF 11.2395 0.5548
CASKSGLAGIAKNIQYF 6.4135 0.0006
CASSRSPGRDEQFF 5.2705 ND
CASRNSQLFYEQYF 3.4798 ND
CASRSGEAKYF 3.4417 0.0048
CASSPRVTSSGNTIYF 3.2512 ND
CSVILQGNTEAFF 3.0734 0.0012
CASSYPLGGGNQPQHF 2.9337 0.0006
CASSQGPTGTQYF 2.7305 ND
R3 CASSPRGLITDTQYF 29.2095 0.0006
CSAPGLAGGNEQFF 13.9130 0.0006
CASSFEGEQYF 4.6245 0.0012
CASSLGQGAGQPQHF 2.2925 0.0012
CASNLGDRWLGEQFF 1.7391 ND
CASSQGGQGFLGYTF 1.5415 ND
CASFRGRTEKLFF 1.4625 ND
CASSKGVEAFF 1.4625 0.0006
CASRPSGIPDTQYF 1.3834 ND
CASSEVDGLDGYTF 1.2253 0.0006
DPB1*09:01-
specific 
cD137+cD4+ 
cells
amino acid sequence Frequency 
in cultured 
sample (%)
Frequency in 
pre-culture 
sample (%)
R1 CAWSVNSNEKLFF 22.5659 0.0405
CASSVTGEVMNTEAFF 17.93 0.0006
CASSQTSLYEQYV 3.9200 ND
CASSRGRDYNSPLHF 3.8976 0.0061
CASSGLGTLGSNQPQHF 3.2530 0.0006
CASSSRRVNSPLHF 3.2455 0.0072
CATSDRGLNYGYTF 3.1337 0.0028
CASSRAADSNEKLFF 2.1426 0.0061
CASTRTGDYGYTF 1.8556 ND
CASSYVRALSTDTQYF 1.2632 ND
R2 CASSSPPGETQYF 16.3787 0.0036
CSAATSYNSPLHF 13.5453 ND
CASSLRGANEQFF 8.1548 0.0006
CASSLAHLRQTAYEQYF 6.6344 0.5548
CASSLKPGYEQYF 3.8010 ND
CASKSGLAGIAKNIQYF 3.6628 0.0006
DPB1*09:01-
specific 
cD137+cD4+ 
cells
amino acid sequence Frequency 
in cultured 
sample (%)
Frequency in 
pre-culture 
sample (%)
CSARETGNTEAFF 3.5936 ND
CASSPGRSNTGELFF 3.1790 ND
CASSATRTGGGYGYTF 2.7643 0.0042
CASSPDYSNQPQHF 2.2806 0.0018
R3 CASSMEGNQPQHF 22.1416 ND
CASSLMSGRNSGEQYF 9.1468 0.0024
CSAKQAEYEQYF 7.6760 ND
CASSYGAGASYMNEQFF 6.4874 0.0006
CASSPSTDTQYF 4.4525 0.0065
CASSPRTGEQYF 4.4223 ND
CASGTGVNTEAFF 2.3169 ND
CSASDRGLYEQYF 1.7024 0.0006
CASSLRLAALYGYTF 1.2894 ND
CISGDSYEQYV 1.1685 0.0006
CDR3, complementarity-determining region 3; ND, not detected.
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we sought to dissect the effect of the extent of variation in this 
region of the HLA-DP molecule exerted indirectly via thymic 
selection on the diversity of clones expanded from the alloreac-
tive TCR repertoire. DPB1*09:01 and DPB1*04:01/*04:02 differ 
at 13 and 10 positions in exon 2, respectively. It is expected that 
the peptide repertoires of these molecules differ substantially, 
providing a plausible explanation for strong alloreactivity and 
diverse TCR responses observed among self-DPB1*04:01,*04:02 
individuals. On the other hand, the DPB1*02:01 exon 2 differs 
from DPB1*04:02 only at position 69 (E69K). This makes it likely 
that the peptide repertoires of these two molecules overlap to a 
certain extent. Indeed, analysis of the peptide binding motifs for 
DPB1*02:01 (31) and DPB1*04:02 (unpublished data, manuscript 
in preparation) show that peptide position P4, which interacts 
with the pocket formed in part by the side chain of position 69 
on the alpha-helix of the DP beta polypeptide, is the only posi-
tion that seems to differ significantly between these two alleles, 
with DPB1*02:01 having affinity for lysine and DPB1*04:02 for 
glutamic acid at P4. Importantly, position 69 on the DPB1*02:01 
molecule has been shown to impact the recognition of this mol-
ecule by monoclonal antibodies (32), bone marrow recipient– 
donor mixed-lymphocyte reactions (10), and the lysis of 
DPB1*02:01-expressing cells by alloreactive T cell clones (33, 34). 
Moreover, mutation of position 69 in DPB1*02:01 was shown to 
impact the class II-associated invariant chain-derived peptide 
binding affinities of pockets 4 and 6 (35). Interestingly, this 
position of the DPB1 molecule and the specific amino acid E69K 
change have been previously identified as having a strong impact 
on the generation of alloreactivity against DPB1*09:01 (13).
Of note, some studies have reported that class I HLA molecules 
with numerous sequence differences do not elicit an allogeneic 
cytotoxic lymphocyte response (36) and that such highly diverged 
mismatches might be acceptable in HSCT (37). We have not 
observed this phenomenon in our CD4+ assays, neither with 
DPB1*09:01 nor with other alleles having several amino acid 
TaBle 3 | Continued
(Continued )
FigUre 6 | Expansion of DPB1-specific alloreactive clones detected in pre-culture samples. Fold expansion among alloreactive T cell clones present in the cultured 
samples and that could be detected in the pre-culture samples for each responder (R) was quantified and plotted (y axis) against their frequency in the pre-culture 
sample (x axis). The size of the circle represents the share of each clone in the total cultured set. Highest values (%) are indicated for each sample. Left panels, clones 
responding against DPB1*02:01; right panels, clones responding against DPB1*09:01. As shown in Figure 7a (purple dots), 177, 146, and 92 clones against 
DPB1*02:01, and 249, 43, and 112 clones against DPB1*09:01 were detected in both the cultured and the pre-culture samples for R1, R2, and R3, respectively.
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differences when compared to the autologous alleles (unpublished 
data). Intuitively, more amino acid differences in the peptide-
binding grove would generate more divergent peptide repertoires 
resulting in a lower indirect effect of thymic selection and higher 
alloreactivity, something that lies at the basis of the TCE model.
In the context of allogeneic HSCT, compatibility between 
donor and recipient for polymorphic HLA plays a central role in 
the balance between the detrimental graft-vs.-host and therapeu-
tic graft-vs.-leukemia effects (38, 39), both mediated mainly by 
alloreactive T cell responses. Because of this, the search of HLA 
permissive mismatches, which contribute to cure the patient’s 
malignancy while reducing the toxicity of the transplant, is a 
major goal in HSCT (40). Permissiveness to DPB1 mismatches 
is now a well-established phenomenon in HSCT, both clinically 
(14, 15) and in vitro (9, 12, 41), with permissive mismatches (i.e., 
those involving two alleles of the same T cell epitope, TCE, group, 
and that share structural similarities) conferring significantly 
lower risks of relapse without significant increases in non-relapse 
mortality when compared to DPB1 allele matches after HSCT for 
hematologic malignancies (14, 42, 43).
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FigUre 7 | Continued
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Clinically, a mismatch involving a donor who is self-
DPB1*04:01,*04:02 and a patient bearing DPB1*02:01 would 
currently be considered permissive, whereas one involving a 
patient with a self-DPB1*09:01 is considered non-permissive. 
Our data show that, contrary to the strength of the alloreactive 
response, the diversity of the alloreactive clones elicited by such a 
permissive mismatch does not seem to be impacted by the num-
ber of amino acid differences in the peptide-binding groove. This 
feature is desirable for the therapeutic effect of HSCT: moderate 
alloreactivity levels combined with a sufficiently broad repertoire 
maximizing the capacity of donor-derived T cells of effectively 
recognizing malignant patient cells while minimizing GvHD.
Since permissiveness was not predicted by significant differences 
in terms of the size of the set of responding TCR clones, it is possible 
that a qualitative characteristic of the HLA–TCR interaction influ-
encing events downstream of TCR recognition (44, 45) and shaped 
by thymic selection might be responsible for this phenomenon 
(16, 46). Thymic education in a self-DPB1*04:01,*04:02 individual 
could have an indirect effect on the allogeneic repertoire capable of 
reacting to a structurally related molecule such as DPB1*02:01, by 
reducing the affinity of the binding to the allogeneic molecule. This 
would not result in more restricted reacting TCR repertoires but in 
lower activation and proliferation of the T cells. We cannot, however, 
rule out that TCR repertoire breadth plays a role in permissiveness 
to other specific allelic combinations. Moreover, DPB1*02:01 might 
still represent a separate TCE group (47) and hence behave differ-
ently with respect to other alleles sharing similarity to DPB1*04:02. 
More research into this question is warranted.
Interestingly, low-abundance T cell clones, which have been 
shown to constitute a significant amount of the alloreactive 
response in vitro (29) and in vivo (30), seem to represent a higher 
proportion of the TCR clone sets against DPB1*09:01 than against 
DPB1*02:01. A possible explanation for this observation could be 
that a more functionally distant allele such as DPB1*09:01 might 
elicit stronger TCR signaling that could help to beat the threshold 
to extract these specificities from the deep pre-culture repertoire 
thanks to better proliferative signals.
Recent reports have shown a potential effect of differential 
3′UTR-controlled expression levels on permissiveness of DPB1 
mismatches in the context of HSCT (48, 49). This model would 
not play a role in the results presented in this study since the 
HeLa cell system utilized does not include the 3′UTR region of 
this gene (18). However, we cannot dismiss a potential effect of 
this model on the alloreactive TCR repertoires against HLA-DP 
molecules in a physiological setting.
Our study is limited by the number of subjects included, the 
use of the HeLa system (i.e., of a non-physiological antigen pre-
senting cell to stimulate our alloreactive T cells), and the use of 
total CD4+ responder T cells. Although we have been unable to 
identify any “public” TCR clones responding against DPB1*02:01 
and/or DPB1*09:01, a larger study with a significantly larger 
number of subjects would be required to rule out the existence of 
such clones in the population. Similarly, the analysis of a potential 
effect of responder age and the frequency of memory CD4+ 
T cells in their repertoire on the clonality of HLA-DP alloreac-
tive cells would require a larger number of samples. The use of 
HeLa cells transduced to express specific DPB1 alleles, although 
extremely useful experimentally, could skew our results due to 
the underlying peptidome of this non-hematopoietic tumor cell 
line. Moreover, we have not addressed the question whether the 
naïve and memory CD4+ repertoires could behave differently 
in alloresponses, something that has been previously suggested 
(50, 51). In addition, despite the high level of over 90% purity 
of our CD137+ samples, a confounding effect of contaminating 
CD137− cells especially on rare CDR3 sequences cannot be ruled 
out. Finally, CD4+ T cells reactive against HLA class I molecules 
have been described (52, 53). However, their impact on our results, 
if any, must be minimal, since very low levels of activation were 
observed when the responder cells were restimulated with the 
HeLa expressing the autologous DPB1 allele, which would express 
the same class I molecules as those transduced with the allogeneic 
molecules.
In conclusion, our study, the first one to comparatively address 
TCR diversity in responses to similar or dissimilar allogeneic 
HLA-DP molecules by NGS immunosequencing, shows proof-
of-principle evidence for the novel concept that limited strength 
alloreactivity can coexist with broad TCR diversity, providing a 
potential platform for clinically favorable DPB1 mismatches in 
allogeneic HSCT. The potential role for in  vitro pre-transplant 
low-abundance clones, revealed solely through the power of 
NGS immunosequencing, as personalized clinical biomarkers in 
HSCT needs to be further clarified by in vivo tracking of expanded 
clones in patients with alloreactivity against DPB1 mismatches.
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FigUre 7 | Low abundance pre-culture T cell clones represent a substantial part of the alloreactive clones elicited against HLA-DPB1 molecules with higher share 
against DPB1*09:01. (a) Clone (CDR3 amino acid) pairwise scatter plots between pre-culture repertoires and CD4+CD137+ cells responding against DPB1*02:01 
(top panels) and DPB1*09:01 (bottom panels) are shown for each responder (R). Low-abundance DPB1-alloreactive clones (orange dots in the pairwise scatter 
plots) were defined as those present in the cultured sample (x axis) and not detected in the respective pre-culture repertoire (y axis). The number and percentage of 
low abundance clones relative to the total number of clones detected in the cultured sample are shown. (B) The share (cumulative frequency) of low abundance 
clones was quantified for clones responding against DPB1*02:01 (top panels) or DPB1*09:01 (bottom panels) in each subject. The average cumulative frequency for 
low-abundance clones against DPB1*02:01 and DPB1*09:01 was 36.3 and 50.6%, respectively.
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